Canadians with Waldenström’s Macroglobulinemia who meet inclusion requirements may want to consider participation in a new study of Beigene’s BGB-16673, a Bruton Tyrosine Kinase Targeted Protein Degrader.  To help in your understanding of a BTK Degrader, see our recent post comparing them to BTK inhibitors (BTKi).

Official title of the study: A Phase 1/2, Open-Label, Dose Escalation and Expansion Study of the Bruton Tyrosine Kinases Targeted Protein Degrader BGB-16673 in Patients with B-cell Malignancies.

Canadian Study Locations Now Recruiting:

  • Calgary, AB:  Arthur Child Comprehensive Cancer Centre
  • Edmonton, AB:  Cross Cancer Institute
  • Laval, QC:  Université de Laval, Hôpital de l’enfant Jésus, Centre Integre de Cancerologie
  • Vancouver, BC:  British Columbia Cancer Agency, Vancouver Centre
  • Toronto, ON:  Princess Margaret Cancer Centre

To learn more, see the trial’s description on the NIH website.